Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 17;12(8):2311.
doi: 10.3390/cancers12082311.

Time to Next Treatment as a Meaningful Endpoint for Trials of Primary Cutaneous Lymphoma

Belinda A Campbell  1   2 , Julia J Scarisbrick  3 , Youn H Kim  4 , Ryan A Wilcox  5 , Christopher McCormack  6   7 , H Miles Prince  8   9
Affiliations

Time to Next Treatment as a Meaningful Endpoint for Trials of Primary Cutaneous Lymphoma

Belinda A Campbell et al. Cancers (Basel). .

Abstract

Time to next treatment (TTNT) is an emerging endpoint in clinical studies of primary cutaneous T-cell lymphomas (CTCL), with utility as a surrogate marker for the "duration of clinical benefit". TTNT provides a highly clinically meaningful endpoint that uniquely reflects not only the duration of treatment efficacy on disease and symptom control, but also incorporates the patient experience by accounting for patient compliance and tolerance to the studied therapy(s). Given the distinct challenges of pin-pointing the exact date of progression in patients with multi-compartmental CTCL, TTNT overcomes many of the shortcomings of conventional, disease-focused, clinical endpoints in primary CTCL research. Although widely accepted in clinical research for numerous other incurable malignancies, TTNT currently lacks a standardised definition. In this paper, we describe the value of TTNT as a clinical endpoint, review the applications of TTNT in primary CTCL research, and propose a standardised definition of TTNT to be applied in future clinical research of primary CTCL therapies.

Keywords: clinical endpoint; clinical trials; primary cutaneous lymphomas; study design; time to next treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Olsen E.A., Whittaker S., Kim Y.H., Duvic M., Prince H.M., Lessin S.R., Wood G.S., Willemze R., Demierre M.-F., Pimpinelli N., et al. Clinical end points and response criteria in mycosis fungoides and Sézary syndrome: A consensus statement of the international society for cutaneous lymphomas, the United states cutaneous lymphoma consortium, and the cutaneous lymphoma task force of the european organisation for research and treatment of cancer. J. Am. Soc. Clin. Oncol. 2011;29:2598–2607. doi: 10.1200/JCO.2010.32.0630. - DOI - PMC - PubMed
    1. Hughes C.F., Khot A., McCormack C., Lade S., Westerman D.A., Twigger R., Buelens O., Newland K., Tam C., Dickinson M., et al. Lack of durable disease control with chemotherapy for mycosis fungoides and Sezary syndrome: A comparative study of systemic therapy. Blood. 2015;125:71–81. doi: 10.1182/blood-2014-07-588236. - DOI - PubMed
    1. Hanel W., Briski R., Ross C.W., Anderson T.F., Kaminski M.S., Hristov A.C., Wilcox R.A. A retrospective comparative outcome analysis following systemic therapy in mycosis fungoides and sezary syndrome. Am. J. Hematol. 2016;91:E491–E495. doi: 10.1002/ajh.24564. - DOI - PubMed
    1. Papps T., McCormack C., Buelens O., Van der Weyden C., Twigger R., Campbell B.A., Dickinson M., Prince H.M. A comparative analysis of histone deacetylase inhibitors for the treatment of mycosis fungoides and sezary syndrome. Br. J. Dermatol. 2019 doi: 10.1111/bjd.18522. - DOI - PubMed
    1. Campbell B.A., Ryan G., McCormack C., Tangas E., Bressel M., Twigger R., Buelens O., van der Weyden C., Prince H.M. Lack of durable remission with conventional-dose total skin electron therapy for the management of sezary syndrome and multiply relapsed mycosis fungoides. Cancers. 2019;11:1758. doi: 10.3390/cancers11111758. - DOI - PMC - PubMed

LinkOut - more resources